Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Lupus Foundation Of America Web Chat Explores "Your Skin And Lupus"
Approximately two-thirds of the 1.5 million Americans living with lupus will develop some type of skin disease. Lupus is an autoimmune disease in which the immune system is unbalanced causing it to become destructive to any organ and tissue in the body. Skin disease in lupus can cause rashes or sores (lesions), most of which will appear on sun-exposed areas, such as a person"s face, ears, neck, arms, and legs. In addition, 40-70 percent of people with systemic lupus will find that their disease is made worse by exposure to ultraviolet (UV) rays from sunlight or artificial light. For this and other reasons, people with lupus are advised to take steps to protect themselves from exposure to UV light.
generic viagra online
New Implantable Device Could Track Tumor's Growth
Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but only offer a snapshot of the tumor at a single moment in time.
News of the day
What Is First Aid? What Is The Recovery Position?
Globally, millions of people die each year as a result of accidents or serious injury. Unfortunately, many of those deaths could have been prevented had first aid been administered at the scene immediately, before the emergency services arrived. First aid, or emergency first aid is the care that is given to an injured or sick person prior to treatment by medically trained personnel. According to Medilexicon"s medical dictionary, first aid is "Immediate assistance administered in the case of injury or sudden illness by a bystander or other layperson, before the arrival of trained medical personnel."
Endocrinology

Analysis Of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects Of Sucrose-Formulated Recombinant Factor VIII

New data pooled from four large, "real world" post-marketing surveillance studies showed that sucrose-formulated recombinant factor VIII (rFVIII-FS) reduced bleeding and provided data regarding adverse events in more than 950 patients with mild-to-severe hemophilia A. Additionally, rates of inhibitor formation were reported in both previously treated and previously untreated patients. The data were presented at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH).(1)(2) In this analysis, the investigators judged rFVIII-FS hemostasis to be "good" or "very good" in 98.9 percent of patients. Serious adverse drug reactions were seen in 1.1 percent of patients and new (de novo) inhibitors were observed in 0.8 percent of patients. "In a "real world" setting, these data reflect some of the extensive global clinical experience with rFVIII-FS," said Georg Lemm, M.D., Ph.D., vice president, Global Clinical Development, and head, Hematology Group, Bayer Schering Pharma. "It is particularly noteworthy that a low rate of inhibitor formation was observed in this analysis of data pooled from post-marketing surveillance studies. Inhibitor formation is a significant challenge for both clinicians and their patients, and its treatment is costly and requires significant time to overcome." Open label study investigating the efficacy of prophylactic versus on-demand rFVIII-FS treatment In another presentation, (3) data from an open label clinical study that enrolled 20 adult men with severe hemophilia A (with and without target joints) demonstrated that patients who were changed from on-demand to prophylactic (preventive) infusions of rFVIII-FS had significantly reduced median joint bleeds per 6-month treatment period (zero events versus 15.0 events, respectively; PAbout Hemophilia A Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A is the most common type of hemophilia and is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately 400,000 people around the world have hemophilia A. About Bayer HealthCare Pharmaceuticals Inc. Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a subsidiary of Bayer Corporation. One of the world"s leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women"s Healthcare. The company"s aim is to provide products that will improve human health worldwide by diagnosing, preventing and treating diseases. Forward-looking statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports filed with the Frankfurt Stock Exchange. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References (1) Fukutake K, et al. Post-marketing experience with sucrose-formulated recombinant factor VIII in patients with hemophilia A. Poster no. PP-MO-577; XXII Congress of the International Society on Thrombosis and Haemostasis. (2) Fukutake K, et al. Inhibitor formation with sucrose-formulated recombinant factor VIII in patients with hemophilia A: Results from post-marketing surveillance studies. Poster no. PP-WE-579; XXII Congress of the International Society on Thrombosis and Haemostasis. (3) Collins P, et al. Efficacy of secondary prophylactic versus on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A with and without target joints. Poster no. PP-TH-584; XXII Congress of the International Society on Thrombosis and Haemostasis. Bayer HealthCare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009